FDA Reviews Sanofi's Lixisenatide With CV Outcomes Data
This article was originally published in Scrip
Executive Summary
Sanofi revealed that its new drug application (NDA) for its once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide is under review at the FDA, which is evaluating the experimental medicine as a treatment for type 2 diabetes.